Fda approves ind submission allowing abvc biopharma to proceed with clinical study of abv-1519 for treatment of non-small cell lung cancer

Fremont, ca, jan. 05, 2023 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology today announced that the us food & drug administration notified the company that the ind application for the proposed clinical investigation of blex 404, the primary active ingredient in abv-1519, for advanced inoperable or metastatic egfr-mutated non-small cell lung cancer has been approved and the study can proceed. the treatment, which is being co-developed by biokey, inc., a wholly owned subsidiary of abvc based in fremont, california and by the rgene corporation was submitted to the fda by rgene on november 30, 2022.
ABVC Ratings Summary
ABVC Quant Ranking